Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial
Scott Berry, Eric VanCutsem(Peter MacCallum Cancer Centre), M. Mazier(PAREXEL International (France)), Fernando Rivera(Marqués de Valdecilla University Hospital), Beatrix Lutiger(Peter MacCallum Cancer Centre), M. Michael(Peter MacCallum Cancer Centre), Albrecht Kretzschmar(Roche (Switzerland)), David Cunningham(Royal Marsden NHS Foundation Trust)
Cited by 44
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k